ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z
  • Abstract Number: 1838
    M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
  • Abstract Number: 1129
    Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever
  • Abstract Number: 2469
    Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
  • Abstract Number: 0194
    Machine Learning Methods to Predict Cardiovascular Risk in Hispanic Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1722
    Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases
  • Abstract Number: 1364
    Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group
  • Abstract Number: 0279
    Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
  • Abstract Number: 0759
    Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media
  • Abstract Number: 0451
    Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome
  • Abstract Number: 0926
    Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
  • Abstract Number: 0925
    Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation
  • Abstract Number: 1635
    Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management
  • Abstract Number: 1367
    Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
  • Abstract Number: 0204
    Making Rheum for Palliative Care in Rheumatology: Perspectives of Rheumatology and Palliative Care Clinicians
  • Abstract Number: 0433
    Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study
  • Abstract Number: 1908
    Male Sex, Medical Comorbidity and Post-procedure Complications Are Associated with Higher In-hospital Mortality After Primary Total Knee Arthroplasty for Osteoarthritis
  • Abstract Number: 0989
    Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
  • Abstract Number: 0726
    Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
  • Abstract Number: 0516
    Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old
  • Abstract Number: 1469
    Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
  • Abstract Number: 1844
    Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
  • Abstract Number: 1558
    Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry
  • Abstract Number: 1091
    Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
  • Abstract Number: 0361
    Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
  • Abstract Number: 1322
    Maternal Antenatal Attachment in Women with Rheumatic Diseases
  • Abstract Number: 2233
    Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
  • Abstract Number: 0307
    Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes
  • Abstract Number: 0342
    Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis
  • Abstract Number: 0541
    Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
  • Abstract Number: 2624
    Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
  • Abstract Number: 1308
    Measuring the Educational Impact of a Collaboration Between RheumMadness and TheMednet
  • Abstract Number: 0973
    Mechano-transduction via MRTF-A Pathway Is Required for Cytokine Release by Scleroderma Macrophages
  • Abstract Number: 1230
    Mediating Role of Pain Catastrophizing in Racial Disparities in Knee Osteoarthritis Pain Among Non-Hispanic White and Asian Americans: A Pilot Study
  • Abstract Number: 1217
    Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California
  • Abstract Number: 0635
    Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients
  • Abstract Number: 1809
    Melanocytes Are Driven Toward an Antigen Presentation Phenotype Through UV-Induced Keratinocyte Crosstalk and Exposure to Type I Interferons in Patients with Cutaneous Lupus Erythematosus
  • Abstract Number: 1788
    Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus
  • Abstract Number: 2330
    Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
  • Abstract Number: 2479
    Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
  • Abstract Number: 0277
    Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation
  • Abstract Number: 0457
    Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
  • Abstract Number: 2524
    Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis
  • Abstract Number: 0101
    Metabolomic Profiling Reveals a Role for Citric Acid Cycle Dysfunction in Antiphospholipid Syndrome Neutrophils
  • Abstract Number: 1774
    Metabolomics and Lipidomics in Juvenile Localized Scleroderma
  • Abstract Number: 1415
    Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study
  • Abstract Number: 0404
    Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData
  • Abstract Number: 0131
    Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
  • Abstract Number: 1366
    Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study
  • Abstract Number: 2240
    Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis
  • Abstract Number: 0075
    Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
  • Abstract Number: 0315
    Microvascular Abnormalities Are Present in Autonomic Dysfunction: Results of a Prospective Study
  • Abstract Number: 1110
    Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
  • Abstract Number: 2213
    Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis
  • Abstract Number: 0314
    Microvascular Differences Between Acute and Chronic Cutaneous Graft versus Host Disease
  • Abstract Number: 1158
    Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
  • Abstract Number: 2189
    Migratory Arthritis in Children: What Besides Rheumatic Fever?
  • Abstract Number: 1590
    Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
  • Abstract Number: 1758
    Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
  • Abstract Number: 0545
    Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
  • Abstract Number: 1772
    Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death
  • Abstract Number: 1404
    Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
  • Abstract Number: 0163
    Modification of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis, Clinically Amyopathic Dermatomyositis, and Immune-mediated Necrotizing Myopathy
  • Abstract Number: 2551
    Modified Delphi Process to Propose an Equity Measurement Roadmap in Rheumatology
  • Abstract Number: 0042
    Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model
  • Abstract Number: 0099
    Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome
  • Abstract Number: 1810
    Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus
  • Abstract Number: 0935
    Molecular Degraders of Extracellular Protein (MoDEsTM) Rapidly and Effectively Remove Interstitial IgG and Disease-Relevant Immune Complexes Through Endo-lysosomal Degradation in the Liver
  • Abstract Number: 0711
    Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
  • Abstract Number: 1782.5
    Monocytes from HLA B27 Positive Enthesitis Related Arthritis Patients Are More Activated Than HLA B27 Negative Patients
  • Abstract Number: 0144
    More Than a Monolith: Disaggregating Rheumatoid Arthritis Prevalence Among Asian American Subgroups
  • Abstract Number: 0645
    Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
  • Abstract Number: 2297
    Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry
  • Abstract Number: 2493
    Mortality in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: Study from a Single University Hospital
  • Abstract Number: 1614
    Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
  • Abstract Number: 2532
    Mortality in Patients with Pre-existing Autoimmune Disease on Immune Checkpoint Inhibitor Therapy
  • Abstract Number: 1215
    Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
  • Abstract Number: 1715
    Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
  • Abstract Number: 0336
    Mortality: Comparison, Causes and Determinants in Subgroups of Idiopathic Inflammatory Myopathies
  • Abstract Number: 1248
    Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
  • Abstract Number: 0696
    MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers
  • Abstract Number: 0234
    MRI of Sacroiliac Joints: Is Contrast Necessary for the Detection of Sacroiliitis?
  • Abstract Number: 1742
    Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care
  • Abstract Number: 1490
    Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
  • Abstract Number: 2636
    Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
  • Abstract Number: 1762
    Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
  • Abstract Number: 1789
    Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus
  • Abstract Number: 1706
    Multi-omic Study in Patients with SITRAME Syndrome
  • Abstract Number: 2426
    Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
  • Abstract Number: 0961
    Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients
  • Abstract Number: 1632
    Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
  • Abstract Number: 1665
    Multicenter Randomized Controlled Trial of Physical Therapy (PT) or Sham PT in Persons with Knee Pain, Meniscal Tear, and Osteoarthritic Imaging Changes
  • Abstract Number: 2633
    Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification
  • Abstract Number: 1307
    Multidisciplinary Participation in Online Rheumatology Discussion Forums
  • Abstract Number: 2452
    Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study
  • Abstract Number: 0296
    Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
  • Abstract Number: 1853
    Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome
  • Abstract Number: PP07
    My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
  • Abstract Number: 1203
    My Shoulder Hurts, What Should I Do? A Systematic Review and Bayesian Network Meta-analysis of Different Injectables in Glenohumeral Osteoarthritis
  • Abstract Number: 2199
    Mycobacterial Infection and Renal and Bladder Malignancy in 2 IFNopathy Patients on High Doses of JAK Inhibitors
  • Abstract Number: 0295
    Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
  • Abstract Number: 0688
    Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching
  • Abstract Number: 0996
    Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition
Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology